Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 May;38(5):497-503.
doi: 10.1007/s40618-014-0204-4. Epub 2014 Dec 6.

Human recombinant follicle stimulating hormone (rFSH) compared to urinary human menopausal gonadotropin (HMG) for ovarian stimulation in assisted reproduction: a literature review and cost evaluation

P E Levi Setti  1 , C Alviggi  2 , G L Colombo  3   4 , C Pisanelli  5   6 , C Ripellino  7 , S Longobardi  8 , P L Canonico  9 , G De Placido  10
Affiliations

Human recombinant follicle stimulating hormone (rFSH) compared to urinary human menopausal gonadotropin (HMG) for ovarian stimulation in assisted reproduction: a literature review and cost evaluation

P E Levi Setti et al. J Endocrinol Invest. 2015 May.

Abstract

Background: Gonadotropins are protein hormones which are central to the complex endocrine system that regulates normal growth, sexual development, and reproductive function. There is still a lively debate on which type of gonadotropin medication should be used, either human menopausal gonadotropin or recombinant follicle-stimulating hormone. The objective of the study was to perform a systematic review of the recent literature to compare recombinant follicle-stimulating hormone to human menopausal gonadotropin with the aim to assess any differences in terms of efficacy and to provide a cost evaluation based on findings of this systematic review.

Methods: The review was conducted selecting prospective, randomized, controlled trials comparing the two gonadotropin medications from a literature search of several databases. The outcome measure used to evaluate efficacy was the number of oocytes retrieved per cycle. In addition, a cost evaluation was performed based on retrieved efficacy data.

Results: The number of oocytes retrieved appeared to be higher for human menopausal gonadotropin in only 2 studies while 10 out of 13 studies showed a higher mean number of oocytes retrieved per cycle for recombinant follicle-stimulating hormone. The results of the cost evaluation provided a similar cost per oocyte for both hormones.

Conclusions: Recombinant follicle-stimulating hormone treatment resulted in a higher oocytes yield per cycle than human menopausal gonadotropin at similar cost per oocyte.

Keywords: Assisted reproduction; Cost evaluation; FSH; Gonadotropins; HMG; Human menopausal gonadotropin; Infertility; Recombinant follicle stimulating hormone; Systematic review.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Identification and selection of the studies to be included
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Parhar IS. Gonadotropin-releasing hormone: molecules and receptors. Amsterdam: Elsevier; 2002.
    1. Donini P, Montezemolo R. Rassegna di Clinica, Terapia e Scienze Affini. A publ biol lab inst serono. 1949;48:3–28.
    1. Rosenberg E, Coleman J, Damani M, Garcia CR. Clinical effect of post menopausal gonadotropin. J Clin Endocrinol Metab. 1962;23:181–189. doi: 10.1210/jcem-23-2-181. - DOI
    1. Lunenfeld B. Treatment of anovulation by human gonadotropins. J Int Fed Gyneacol Obstet. 1963;1:153.
    1. Eshkol A, Lunenfeld B. Purification and separation of follicle stimulating hormone (FSH) and luteinizing hormone (LH) from human menopausal gonadotrophin (HMG) Part III. Acta Endocrinol. 1967;54:919. - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources